Astellas v. Ascent Pharmaceuticals: Xtandi® Generic Patent Litigation Settled With Prejudice
Astellas Pharma, Medivation, and the Regents of the University of California sued Ascent Pharmaceuticals in New Jersey over a generic version of Xtandi® (enzalutamide), asserting three patents. The case resolved in 179 days via a confidential settlement, with all claims and counterclaims dismissed with prejudice and each party bearing its own costs.
Xtandi® ANDA patent fight ends in swift confidential settlement
Filed on 2 January 2025 in the District of New Jersey, this Hatch-Waxman infringement action was brought by Astellas Pharma Inc., Astellas US LLC, Astellas Pharma US Inc., Medivation LLC, Medivation Prostate Therapeutics LLC, and the Regents of the University of California against Ascent Pharmaceuticals Inc. The plaintiffs collectively own or license three U.S. patents — US7709517B2, US8183274B2, and US12161628B2 — that protect enzalutamide, the active ingredient in Xtandi®, a blockbuster androgen receptor inhibitor used in prostate cancer treatment. Ascent had filed an Abbreviated New Drug Application (ANDA) seeking to market a generic version of Xtandi® capsules.
The case closed on 30 June 2025, 179 days after filing, via a consent dismissal order jointly requested by all parties. The court dismissed all of Astellas’s patent claims and all of Ascent’s counterclaims with prejudice, and ordered each party to bear its own costs. Critically, the court explicitly retained jurisdiction to enforce the parties’ confidential settlement agreement — a formulation that strongly suggests the resolution includes negotiated terms such as a licensed market-entry date for Ascent’s generic, royalty arrangements, or other commercial restrictions that remain outside the public record.
A 179-day resolution is notably fast for ANDA patent litigation, which typically runs two or more years through fact discovery and expert reports alone. The speed suggests the parties may have identified a commercial path — likely an agreed launch date — early in the litigation rather than litigating through trial. What drove Astellas to settle rather than seek the automatic 30-month stay’s full benefit, and on what terms Ascent may enter the market, are questions the public record does not answer. The inclusion of US12161628B2, a more recent continuation patent, also suggests Astellas may have been reinforcing its exclusivity position on Xtandi® ahead of near-term generic competition.
Filing to Dismissed with Prejudice in 179 days
179 days — resolved well under the median ANDA litigation timeline of ~2–3 years
Dismissed with prejudice: what the consent order means for both parties
Dismissal with prejudice bars re-filing on the same patents
A dismissal with prejudice is a final adjudication on the merits — Astellas cannot re-sue Ascent on these three patents for the same ANDA product. The court’s retention of jurisdiction to enforce the settlement agreement is the operative mechanism: it signals a binding private contract governs the parties’ future conduct, likely including when and how Ascent may enter the market. This is the standard architecture of a Hatch-Waxman settlement.
Final, non-re-fileable dismissalAstellas retains leverage through confidential settlement terms
Though Astellas’s infringement claims are formally dismissed, the with-prejudice structure tied to an enforceable settlement agreement typically means Astellas secured agreed commercial terms — most commonly a defined licensed launch date for Ascent’s generic. This allows Astellas to control the genericisation timeline of Xtandi® without exposing its patents to the risk of an invalidity finding at trial. Each party bearing its own costs suggests a balanced negotiation rather than a capitulation by either side.
Settlement controls entry dateAscent gains a path to market — terms remain confidential
Ascent’s counterclaims — which likely included invalidity and non-infringement challenges to all three patents — were also dismissed with prejudice, meaning Ascent cannot re-litigate those patent challenges in this forum. In exchange, Ascent almost certainly secured a contractual right to launch its generic at a negotiated future date. The confidential settlement caps Ascent’s litigation cost exposure while providing the market certainty needed to progress its ANDA through FDA approval.
Negotiated market access securedXtandi® exclusivity window partially preserved for now
Xtandi® (enzalutamide) is a high-value prostate cancer therapy. The swift settlement — before any substantive patent rulings — means the validity of all three asserted patents remains unchallenged in the public record, preserving their deterrent value against other ANDA filers. Competitors monitoring this case should note that Astellas still holds US12161628B2, a later-filed continuation, which may extend the effective exclusivity window beyond the original patent term and could feature in future ANDA disputes.
Exclusivity timeline preservedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Astellas Pharma, Inc. | Company | Multinational pharmaceutical group — holder of US7709517B2, US8183274B2, and US12161628B2 covering enzalutamide (Xtandi®)Search in Eureka ↗ |
| Defendant | Ascent Pharmaceuticals, Inc. | Company | Generic pharmaceutical manufacturer seeking ANDA approval for a generic version of Xtandi® capsulesSearch in Eureka ↗ |
| Plaintiff counsel | ALEXIS M MCJOYNT | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine Clark | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | ERIN AUSTIN | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Katelyn O’Reilly | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Liza M. Walsh | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Venable LLP | Law Firm | Representing Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Walsh Pizzi O’reilly Falanga, LLP | Law Firm | Representing Astellas Pharma, Inc.Search in Eureka ↗ |
| Defendant counsel | Daniela Caro-Esposito | Attorney | Counsel for Ascent Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Gregory S. Gewirtz | Attorney | Counsel for Ascent Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Lerner David, LLP | Law Firm | Representing Ascent Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent dismissal order is notable for its bilateral finality and its express retention of court jurisdiction — a pairing that confirms the resolution is contractual, not merely procedural. Both offensive claims and defensive counterclaims are extinguished with prejudice, meaning neither party can relitigate these patent disputes. The absence of any cost award to either side, and the court’s supervisory role over the settlement agreement, are consistent with a negotiated Hatch-Waxman entry-date licence rather than a concession of infringement or invalidity by either party.
US7709517B2, US8183274B2, US12161628B2 — enzalutamide (Xtandi®) patent estate
The three asserted patents — US7709517B2, US8183274B2, and US12161628B2 — collectively cover the enzalutamide compound, its pharmaceutical compositions, and methods of use for treating castration-resistant prostate cancer, marketed as Xtandi®. US7709517B2 and US8183274B2 represent foundational compound and formulation patents arising from early application filings, while US12161628B2 derives from application US17/959350, a later continuation that extends and reinforces the patent family’s coverage into more recent claim territory. Together, they form a layered exclusivity wall around Xtandi® that any generic entrant must navigate.
Xtandi® (enzalutamide) generated multi-billion dollar annual revenues for Astellas and Pfizer prior to generic entry risk materialising. The strategic significance of this three-patent estate is considerable: the inclusion of a recent continuation (US12161628B2) suggests Astellas has been actively prosecuting new claims to extend enforceable exclusivity, a common tactic in high-value pharmaceutical patent management. Any ANDA filer — not just Ascent — must assess whether their formulation or method of manufacture reads on all three patents, and whether the continuation’s claims are susceptible to inter partes review or other post-grant challenge.
Should you run an FTO analysis against the Xtandi® enzalutamide patent estate?
Any company developing, manufacturing, or commercialising a generic or biosimilar version of enzalutamide — or working on androgen receptor inhibitor formulations in the prostate cancer space — should conduct a current freedom-to-operate analysis against all three asserted patents. US12161628B2, as the most recently granted continuation, warrants particular attention: continuation patents often carry claim sets refined in light of the original prosecution and prior art, and may capture product configurations not addressed in earlier FTO studies.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map their enzalutamide or androgen receptor inhibitor product against the full Astellas/Regents patent family, identify claim-by-claim exposure, and flag continuation filings or divisionals that could extend exclusivity beyond US12161628B2. With the Xtandi® settlement terms confidential and future ANDA litigation likely, a structured FTO is an essential step before committing to formulation or manufacturing investment.
Run a freedom-to-operate analysis on US7709517B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA patent cases in pharmaceutical District Court litigation
Explore related ANDA infringement actions in New Jersey District Court involving branded pharmaceutical patents and generic market-entry disputes.
What this case signals for the pharmaceutical ANDA IP landscape
A 179-day settlement in a multi-patent Hatch-Waxman case reveals how branded pharma manages generic entry risk without litigating to trial.
Swift Hatch-Waxman settlements protect patent validity records
By settling before any claim construction or invalidity ruling, Astellas ensures none of its three Xtandi® patents are declared invalid or unenforceable in the public record. This is a deliberate litigation strategy — preserving the patents’ strength against future ANDA challengers. Other branded pharma companies defending blockbuster drugs should weigh the same calculus: trial risk vs. commercial certainty.
Court-retained jurisdiction signals a structured entry date agreement
When a district court retains jurisdiction to enforce a settlement, it signals that the agreement contains ongoing obligations — in ANDA litigation, almost invariably a licensed launch date. Parties and investors tracking Xtandi® generic competition should watch for FDA tentative approval updates from Ascent, which will likely signal when the negotiated entry window opens.
Astellas v Ascent — key questions answered
Astellas and co-plaintiffs (Medivation entities and the Regents of the University of California) asserted three patents: US7709517B2, US8183274B2, and US12161628B2. All three relate to enzalutamide, the active ingredient in Xtandi® capsules, covering the compound, formulations, and methods of treating prostate cancer.
Dismissed with prejudice means the case is terminated on a final basis — Astellas cannot re-file the same infringement claims against Ascent on these three patents for the same ANDA product, and Ascent cannot re-litigate its invalidity counterclaims in this forum. It reflects a binding resolution, here linked to a confidential settlement agreement that the court retains jurisdiction to enforce.
Neither party received a judicial ruling on the merits. The case settled and was dismissed with prejudice by consent, with each party bearing its own costs. This outcome is consistent with a negotiated licence — typically including an agreed generic market-entry date — rather than a win or loss on patent validity or infringement.
The court’s retention of jurisdiction to enforce the settlement agreement is standard practice when a Hatch-Waxman case resolves by settlement. It gives either party recourse to the federal court if the other breaches the settlement terms — for example, if Ascent were to launch its generic before a contractually agreed date. This mechanism makes the settlement legally binding and court-enforceable.
US12161628B2 is a continuation patent filed under application US17/959350, representing a later addition to the Astellas/Regents enzalutamide patent family. Its inclusion alongside the earlier patents US7709517B2 and US8183274B2 suggests Astellas was asserting its broadest and most current claim coverage to maximise the scope of its Hatch-Waxman exclusivity position and deter or delay generic entry by Ascent.
PatSnap Eureka searches patents and litigation data to answer instantly.